Ginkgo Bioworks Holdings 주식 (NYSE: DNA)

에 대한 최신 뉴스 Ginkgo Bioworks Holdings (NYSE:DNA) 주식

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.

Equities

News

Markets

ETFs

ACHR

ARKK

AVAV

BLDE

NTLA

TDOC

TSLA

VERV

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:TSLA)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

ARKW

COIN

ROKU

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:ROKU)와 코인베이스 글로벌(NASDAQ:COIN)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래

아크 인베스트는 로쿠 $730만의 주식을 매수, 비트코인 하락에 코인베이스 주식을 매각

ARCT

ARKQ

MKFG

NVDA

2024년 6월 25일 화요일, 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 상당한 시장 변동성 속에서 엔비디아(NASDAQ:NVDA)와 로쿠(NASDAQ:ROKU)에서 상당한 거래를 했다. 이러한 거래는 아크의 다양한 ETF가 이행한 일련의 거래의 일부였다.

아크 인베스트는 주가 반등 속에 엔비디아 주식에서 $430만 매도, 로쿠 주식을 매수

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings Inc

Metaverse Dualchain Network Architecture

DeNA Co Ltd

DNAPRINT GENOMICS INC by DNAPrint Genomics, Inc.

DNA Print Genomics Inc

DNA Brands Inc

Earnings

Guidance

B&G Foods Sees FY24 Net Sales $1.920B-$1.950B Vs $1.951B Est.; Adj. Diluted EPS $0.67-$0.77

Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. The company reported quarterly sales of $51.500 million which beat the analyst consensus estimate of $50.696 million by 1.59 percent. This is a 7.29 percent increase over sales of $48.000 million the same period last year.

Earnings Beats

CTKB

Cytek Biosciences Q3 2024 GAAP EPS $0.01 Beats $(0.02) Estimate, Sales $51.500M Beat $50.696M Estimate

Full year fiscal 2025 guidance:2
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Current</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$2,369</td>
<td colspan="1" rowspan="1">$2,391</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating margin3</td>
<td colspan="1" rowspan="1">23.0&nbsp;%</td>
<td colspan="1" rowspan="1">23.2&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS</td>
<td colspan="1" rowspan="1">$5.78</td>
<td colspan="1" rowspan="1">$5.87</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted revenue</td>
<td colspan="1" rowspan="1">$2,353</td>
<td colspan="1" rowspan="1">$2,375</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating margin</td>
<td colspan="1" rowspan="1">22.7&nbsp;%</td>
<td colspan="1" rowspan="1">22.8&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
<a href="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.html"><img src="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.jpg" alt="Key Call-Outs" /></a>

JKHY

Jack Henry & Associates Sees FY25 EPS $5.78-$5.87 Vs $5.83 Est.; Revenue $2.353B-$2.375B Vs $2.37B Est.

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) narrows FY2024 sales outlook from $495.00 million-525.00 million to $500.00 million-510.00 million.

SWIM

Latham Group Narrows FY2024 Sales Guidance from $495.00M-525.00M to $500.00M-510.00M  VS Est. 512.39M

Meme cryptocurrency Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) has experienced a surge in trading volume and price activity leading up to the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a>
A Benzinga poll asks readers to choose whether a victory by Donald Trump or Kamala Harris in the election could have a more positive impact on Dogecoin in 2025.
What Happened: Dogecoin is up 12% to $0.1761 on Tuesday, with the meme cryptocurrency seeing increased activity likely related to the 2024 election <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s">and positive mentions </a>of the Department of Government Efficiency, or D.O.G.E. for short, by Elon Musk.
Musk is expected to join the Trump administration if the former president wins the 2024 election. In this role, Musk would seek to cut government inefficiencies and unnecessary departments, a role labeled under the D.O.G.E.
The Tesla CEO and billionaire mentioned D.O.G.E. during his<a href="https://www.benzinga.com/general/education/24/11/41752565/if-you-invested-1-000-in-tesla-stock-the-first-time-elon-musk-was-on-the-joe-rogan-podcast-here"> most recent appearance</a> Monday on "The Joe Rogan Experience" podcast, which is likely contributing to Dogecoin's strong movement on Tuesday.
"For Dogecoin's future in 2025, who would be the better president: Kamala Harris or Donald Trump?" Benzinga recently asked.
The results were:
<ul>
<li>Donald Trump: 72%</li>
<li>Kamala Harris: 28%</li>
</ul>
The Benzinga poll found that respondents believe Trump would be more favorable for the future of Dogecoin, which may not come as a surprise given the former president&#8217;s reputation as a more pro-crypto leader.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Trump, who previously <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38749745/if-you-invested-1-000-in-bitcoin-when-donald-trump-said-the-cryptos-value-was-based-on-thi">spoke out against Bitcoin, </a>reversed course and has appealed to cryptocurrency investors ahead of the 2024 election.
If Trump wins the 2024 election, cryptocurrency investors expect the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies to rise with a more crypto-friendly government in place and the likelihood that SEC Chair Gary Gensler will be replaced.
While Harris has not been as vocal on cryptocurrency as Trump, there is belief that she <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41322645/mark-cuban-defends-kamala-harris-crypto-knowledge-appears-to-take-dig-at-trump-for-selling">could look to advance</a> the sector forward if she wins the election.
Either way, Dogecoin could see high volatility during the week as the 2024 election outcome is expected to take some time to make official.
With a price of $0.1761 on Tuesday, Dogecoin is nearing its one-month high of $0.1792.
Over the last 52 weeks, Dogecoin has traded between $0.07028 and $0.2266. Dogecoin hit all-time highs of $0.7376 back in May 2021.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41410605/if-you-invested-100-in-dogecoin-when-elon-musk-first-tweeted-about-the-meme-crypto-heres-h">If You Invested $100 In Dogecoin When Elon Musk First Tweeted About The Meme Crypto, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
The study was conducted by Benzinga from Nov. 4 through Nov. 5, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 134 adults.
Image created with Shutterstock and Midjourney.

Exclusives

$DOGE

Dogecoin Jumps On Election Day: Poll Asks If Trump Or Harris Victory Will Spark 2025 Rally

WIIM

Devon Energy shares are trading higher following a Q3 earnings beat.

Ashford Hospitality Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) reported quarterly AFFO of $(1.71) per share which missed the analyst consensus estimate of $(0.97) by 76.29 percent. This is a 311.11 percent decrease over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $276.60 million which beat the analyst consensus estimate of $268.97 million by 2.84 percent. This is a 19.36 percent decrease over sales of $343.01 million the same period last year.

Earnings Misses

Ashford Hospitality Trust Q3 2024 AFFO $(1.71) Misses $(0.97) Estimate, Sales $276.60M Beat $268.97M Estimate

Jack Henry &amp; Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.61 by 1.24 percent. This is a 17.27 percent increase over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $600.98 million which beat the analyst consensus estimate of $600.11 million by 0.15 percent. This is a 5.18 percent increase over sales of $571.37 million the same period last year.

Jack Henry & Associates Q1 EPS $1.63 Beats $1.61 Estimate, Sales $600.98M Beat $600.11M Estimate

B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.20 by 35 percent. The company reported quarterly sales of $461.10 million which missed the analyst consensus estimate of $473.12 million by 2.54 percent. This is a 8.28 percent decrease over sales of $502.73 million the same period last year.

B&G Foods Q3 2024 Adj EPS $0.13 Misses $0.20 Estimate, Sales $461.10M Miss $473.12M Estimate

NHI is updating its 2024 annual guidance range which includes the following:
NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54;
Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and
Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million;
NAREIT FFO and Normalized FFO revised guidance is primarily due to lower cash lease revenue and interest income assumptions, and a $3.6 million non-cash increase to the credit loss reserve attributable to Senior Living Management. This was partially offset by acquisitions closed since August 2024 funded primarily with forward equity proceeds;
Normalized FAD revised guidance is primarily due to acquisitions closed since August 2024 offset by lower cash lease revenue and interest income assumptions attributable to Senior Living Management.

National Health Investors Updates FY24 NAREIT FFO Per Diluted Share From $4.50-$4.54 To $4.39-$4.41; Normalized FFO Per Diluted Share From $4.52-$4.56 To $4.43-$4.44

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.03) by 2800 percent. This is a 245 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $88.43 million which missed the analyst consensus estimate of $94.21 million by 6.14 percent. This is a 1.75 percent increase over sales of $86.91 million the same period last year.

AVNW

Aviat Networks Q1 Adj $(0.87) Misses $(0.03) Estimate, Sales $88.43M Miss $94.21M Estimate

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) lowers FY2024 sales outlook from $231.00 million-235.00 million to $230.00 million-232.00 million.

VTEX

Vtex Lowers FY2024 Sales Guidance from $231.00M-235.00M to $230.00M-232.00M.

MASI

Masimo Sees Q4 Revenue $581M-$611M; Q4 Adj. EPS $1.35-$1.50

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) sees Q4 sales of $64.800 million-66.800 million vs $67.57 million estimate.

Vtex Sees Q4 Sales $64.800M-66.800M vs $67.57M Est.

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.02) by 3.92 percent. The company reported quarterly sales of $12.500 million which beat the analyst consensus estimate of $11.199 million by 11.62 percent.

SNDX

Syndax Pharmaceuticals Q3 2024 GAAP EPS $(0.98) Beats $(1.02) Estimate, Sales $12.500M Beat $11.199M Estimate

Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. The company reported quarterly sales of $45.086 million which beat the analyst consensus estimate of $43.484 million by 3.68 percent. This is a 10.62 percent increase over sales of $40.758 million the same period last year.

TMCI

Treace Medical Concepts Q3 2024 GAAP EPS $(0.25) Beats $(0.27) Estimate, Sales $45.086M Beat $43.484M Estimate

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.14 by 14.04 percent.

Devon Energy Q3 2024 GAAP EPS $1.30 Beats $1.14 Estimate

Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.01 by 500 percent. The company reported quarterly sales of $7.90 billion which beat the analyst consensus estimate of $7.76 billion by 1.79 percent. This is a 27.75 percent increase over sales of $6.18 billion the same period last year.

CPNG

Coupang Q3 2024 Adj EPS $0.06 Beats $0.01 Estimate, Sales $7.90B Beat $7.76B Estimate

Ever wondered <a href="https://www.benzinga.com/personal-finance/24/10/41193824/are-you-rich-enough-to-be-in-the-top-1-heres-both-the-income-and-net-worth-you-need-to-rank-amon">how your finances measure up?</a> You're not alone. We often think about where we stand compared to others financially – though few of us like to admit it. Getting a sense of your financial health can be motivating, especially when it's not about competition but about setting realistic goals for yourself.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved? <a href="https://www.benzinga.com/money/red-ventures" target="_blank" rel="noreferrer noopener">The percentage may shock you</a>.</li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>
What is Net Worth, Really?
Before diving into numbers, clarifying what "net worth" means is important. Simply put, it's what you own (assets) minus what you owe (liabilities). Assets include things like your home, car, investments and savings. Liabilities are things like mortgages, credit card debt and student loans. Think of net worth as a quick snapshot of your financial health. It's a bigger picture than income alone, revealing how much you've kept.
See Also: Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a>
Net Worth by Income Level
According to the Federal Reserve's latest data, here's how net worth varies across different income brackets:
<ul>
<li>Under $34,600: Median net worth of $14,000, average of $129,700</li>
<li>$34,600-$59,499: Median of $71,000, average of $218,700</li>
<li>$59,500-$91,899: Median of $159,300, average of $385,400</li>
<li>$91,900-$153,099: Median of $307,200, average of $636,800</li>
<li>$153,100-$245,399: Median of $747,000, average of $1,264,700</li>
<li>$245,400 and higher: Median of $2,556,200, average of $6,629,600</li>
</ul>
Upper-income households in the U.S. generally have a net worth significantly higher than lower-income households. According to Pew Research Center, the median net worth of upper-income households is roughly 7.3 times greater than that of middle-income households, and 75 times that of lower-income households.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
What You Can Learn from the Data
There are a few standout takeaways:
Median vs. Average: The U.S. household median net worth is $192,700, while the average is around $1.06 million. The gap highlights how high-net-worth individuals skew the overall average.
Age Matters: Net worth tends to peak for those aged 65-74, averaging around $1.78 million. Years of saving and investing build up.
Education's Impact: A college degree matters here – graduates have over 11 times the net worth of people without a high school diploma.
Location, Location, Location: Urban dwellers typically have higher net worthy than those in rural areas, largely due to property values.
Wealth Gap: Unfortunately, the racial wealth gap remains stark, with white households holding considerably higher net worthy on average than Black and Latino households.
Trending: According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually, <a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor" target="_blank" rel="noreferrer noopener">here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a>
Steps to Boost Your Net Worth
Regardless of where you currently fall, there are practical ways to improve your financial standing:
<ul>
<li>Pay Off High-Interest Debt: Start with credit card balances and other high-interest debts, which can drain your finances fast.</li>
</ul>
<ul>
<li>Save and Invest: Aim to set aside at least 20% of your income and automate it if you can. Investing early helps, too.</li>
</ul>
<ul>
<li>Leverage Retirement Accounts: Contribute to 401(k)s or IRAs, especially if your employer matches contributions.</li>
</ul>
<ul>
<li>Diversify: Spread your investments across stocks, bonds and real estate to manage risk and grow wealth.</li>
</ul>
<ul>
<li>Find Extra Income Streams: Side hustles, freelance work or passive income can boost your finances.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
<ul>
<li>Keep Learning: Educate yourself about personal finance and stay updated on tax strategies and investment options.</li>
</ul>
<ul>
<li>Live Below Your Means: Resist lifestyle inflation even as your income grows. Focus on assets, not material things.</li>
</ul>
<ul>
<li>Invest in Yourself: Whether it's more education or a new skill, growing your potential can lead to better income.</li>
</ul>
<ul>
<li>Check In on Your Goals: Adjust your financial plan as your life and income evolve.</li>
</ul>
<ul>
<li>Seek Professional Guidance: A <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">financial advisor can help you</a> strategize if it feels overwhelming.</li>
</ul>
Comparing your finances to others can motivate you, but remember that everyone's journey is different. Focus on realistic, personal goals that fit your life. Building wealth takes time – it's a marathon, not a sprint. With steady, smart choices, you'll see growth in your net worth over time. Regardless of where you stand now, there's always room to move toward a more secure financial future.
This story was updated to reflect updated research numbers for upper household income net worth vs. lower-income households.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211; <a href="https://www.benzinga.com/money/retire-5mil-nest-egg" target="_blank" rel="noreferrer noopener">How does it compare to the average?</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Personal Finance

Are You Richer Or Poorer Than Your Peers? Here's A Look At The Average Net Worth For Your Income

Masimo Lowers FY24 Revenue From $2.085B-$2.135B To $2.075B-$2.105B Vs $2.100B Est; Raises FY24 Adj. EPS From $3.80-$4.00 To $3.95-$4.10 Vs $3.88 Est

Ginkgo Bioworks Holdings (DNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mark Mas...

Ginkgo Bioworks Holdings: Sell Rating Affirmed with Revised Valuation and Price Target

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA – Research Report), BioMarin Pharma...

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), BioMarin Pharmaceutical (BMRN) and Tactile Systems Technology (TCMD)

Stocks hitting all-time highs: JPM, KO, LMT, UNH, and more

Ginkgo Bioworks regains compliance with NYSE minimum bid price requirement

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

Brendan Smith, an analyst from TD Cowen, maintained the Buy rating on Ginkgo Bioworks Holdings (DNA – Research Report). The associated price target...

Ginkgo Bioworks Holdings: A Buy Rating on Strategic AI Advancements and Market Expansion

The Top Five short crowded stocks in each U.S. sector

Guggenheim SMid Cap Value Fund Q2 2024 Commentary

Interest Rate Regimes And ARKG: Underperformance Explained

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bausch + Lomb Corporation (BLCO – Research Report)...

Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Ginkgo Bioworks Holdings (DNA) and Eli Lilly & Co (LLY)

AAPL

ACHC

ADBE

ADPT

AMKR

AMZN

APLE

ARKG

ASIX

AVGO

BBIO

BEPC

BIRD

BLCO

BMBL

BMRN

CABO

CBRL

CDNA

CERT

CMTL

COHR

CRSP

DASH

DDOG

DLTR

ECVT

ENOV

EVRG

EVTC

EWTX

EXAS

FANG

FDMT

FERG

IART

INBX

INST

IONS

LBPH

LDOS

MGPI

MNTK

MSFT

NAMS

NAPA

NEWT

NFLX

NTST

NXDT

ORIC

PACB

PDCO

PEPG

PHVS

REXR

ROIV

RPRX

RXRX

SDGR

SIRI

TCMD

TMUS

TROW

TRVI

TTWO

TWST

ULCC

VKTX

VTLE

WDAY

Press Releases

Ginkgo Bioworks Reports Second Quarter 2024 Financial Results

Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

Legal

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement

Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

Comments

Ginkgo Bioworks Holdings

뉴스

에 대한 최신 뉴스 Ginkgo Bioworks Holdings (NYSE:DNA) 주식

목요일, 7월 04, 2024

목요일, 6월 27, 2024

수요일, 6월 26, 2024

목요일, 5월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌